Treatment of essential & renovascular HTN, alone or in combination w/ other antihypertensives; CHF not controlled adequately by digitalis & diuretic therapy.
Essential HTN Initially 10 mg. Maintenance: 20 mg/day. Max: 80 mg/day. Renovascular HTN Initially 2.5 or 5 mg, may be adjusted according to BP response. CHF not adequately controlled by diuretics &/or digitalis Initially 2.5 mg. Usual dose: 5-20 mg. Renal impairment Starting dose: CrCl ≤30 mL/min & ≥10 mL/min 5 mg, <10 mL/min, including patient on dialysis 2.5 mg. Max: 40 mg. All doses should be given once daily as a single dose.
Dual blockade of the renin-angiotensin-aldosterone system; symptomatic hypotension; renal function impairment; angioneurotic oedema; patients undergoing major surgery or during anaesth w/ agents that produce hypotension. Pregnancy & lactation. Childn. Elderly.
Decreased renal function (including acute renal failure) w/ ACE inhibitors, ARBs or aliskiren. Potentiation w/ diuretics. May diminish efficacy w/ indomethacin. Concomitant use of K-sparing diuretics (eg spironolactone, triamterene or amiloride) or K supplements. Increase of serum K w/ K supplements & K-sparing diuretics.
Sign Out
